How We Do It

A palliative care consultation service in a hematological malignancy–bone marrow transplant unit


 

Background There is often a lack of collaboration between hematological malignancy–bone marrow transplantation (HM-BMT) units and palliative care (PC) services. In this paper, we describe a quality improvement project that sought to close this gap at a tertiary care hospital in Pittsburgh, Pennsylvania, from August 2006 to May 2010.

Design and methods Through a needs assessment, didactic lectures, clinical consultation, and the informal presence of PC clinicians, the team created a palliative care service in HM-BMT unit of the Western Pennsylvania Hospital in Pittsburgh. The following data were collected for each consult: referral reason, daily pain assessments, whether or not a “goals of care” conversation took place, and hospice enrollment. Lastly, satisfaction surveys were administered.

Results During the program, 392 PC consultations were provided to 256 unique patients. Of these 256 patients, the PC clinicians documented the first goals of care conversations in 67% of patients (n = 172). Of the 278 consults referred for pain, 70% (n = 194) involved reports of unacceptable or very unacceptable pain at baseline. Sixty-six percent (n = 129) of these 194 consults involved reports of pain that was acceptable or very acceptable within 48 hours of consultation. In addition, the hospice referral rate grew from a pre-implementation rate of 5% to 41% (n = 67) of 165 patients who died during the period of program implementation. Lastly, hematological oncologists reported high levels of satisfaction with the program.

Limitations The main limitation of this project is that it was a single institution study.

Conclusion The successful integration of a PC team into a hematological malignancy unit suggests great potential for positive interdisciplinary collaboration between these two fields.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

CAR T-cell therapy: The good and the bad
MDedge Hematology and Oncology
MRI method appears comparable to PET/CT
MDedge Hematology and Oncology
Making K-Ras cancers druggable
MDedge Hematology and Oncology
Proteins may help explain PEL pathogenesis
MDedge Hematology and Oncology
Improving the efficacy of etoposide
MDedge Hematology and Oncology
Allo-SCT can be effective in advanced SS, MF
MDedge Hematology and Oncology
Combo may overcome drug resistance in ALL
MDedge Hematology and Oncology
Immune surveillance prevents DLBCL
MDedge Hematology and Oncology
FDA approves ibrutinib for previously treated CLL
MDedge Hematology and Oncology
Consortium study falls short of expectations
MDedge Hematology and Oncology